Disclaimer: MT1 (Melanotan 1 / afamelanotide) is a research compound not approved by the U.S
Consumer evaluation context: Before purchasing any supplement positioned around GLP-1 terminology, consumers benefit from understanding the distinction between ingredient-level research and product-level evidence, recognizing that dietary supplements and prescription medications represent different categories, and maintaining realistic expectations aligned with available research
They disrupt sleep, hinder physical functioning and mobility, and negatively impact general and mental health ( The precise pathophysiology of muscle cramps persists in its obscurity, and efficacious treatments have yet to be ascertained
Hyvnen, S., Lohi, J., & Tuuminen, T
that's exactly what these communities have been waiting for
Pending the results of the FOCUS Trial and other future studies, how should optometrists approach diabetic patients who go on a GLP-1/GIP agonist